Veterinary Medicines

MAXIVAC PENTA LIOFILIZADO Y SUSPENSIÓN PARA PREPARACIÓN DE SUSPENSIÓN INYECTABLE PARA PERROS

Authorised
  • Leptospira interrogans, serovar Canicola, Inactivated
  • Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Lederle, Live
  • Canine parvovirus, strain Cornell 780916, Live
Download as PDF

Product identification

Medicine name:
MAXIVAC PENTA LIOFILIZADO Y SUSPENSIÓN PARA PREPARACIÓN DE SUSPENSIÓN INYECTABLE PARA PERROS
Active substance:
  • Leptospira interrogans, serovar Canicola, Inactivated
  • Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Lederle, Live
  • Canine parvovirus, strain Cornell 780916, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serovar Canicola, Inactivated
    9.00
    Organisms
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serovar Icterohaemorrhagiae, Inactivated
    9.00
    Organisms
    /
    1.00
    millilitre(s)
  • Canine adenovirus 2, strain Manhattan, Live
    4.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine distemper virus, strain Lederle, Live
    4.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain Cornell 780916, Live
    6.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI03
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Spain
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • Spanish Agency For Medicines And Medical Devices
Authorisation number:
  • 1405 ESP
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 11/07/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 11/07/2025
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 11/07/2025
Download